Volume 4 (Issue 1, 2, 3) 2019
Share on whatsapp
Share on twitter
Share on facebook

Review

Autism Spectrum Disorder: Medications overview

2019, Volume 4, Issue 1, January-April [Download full PDF]


Review

FDA-approves the first therapy in 2018 for the seizures associated with Dravet syndrome

2019, Volume 4, Issue 1, January-April [Download full PDF]


Review

Cannabidiol: FDA approved new drug for the Lennox-Gastaut syndrome and Dravet syndrome: Pharmacotherapeutics review

2019, Volume 4, Issue 1, January-April [Download full PDF]


Review

Caplacizumab: First FDAapproved therapy in 2019 for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura

2019, Volume 4, Issue 1, January-April [Download full PDF]


Review

Stiripentol: New approved drug for the Dravet syndrome: Pharmacotherapeutics review

2019, Volume 4, Issue 1, January-April [Download full PDF]


Review

Siponimod: A new approved oral drug to treat multiple sclerosis

2019, Volume 4, Issue 2, May-August [Download full PDF]


Review

Istradefylline: A new add-on drug to treat off episodes in adults with Parkinson’s disease

2019, Volume 4, Issue 2, May-August [Download full PDF]


Review

FDA recalled Ranitidine: What about the consumers who ate Ranitidine with carcinogenic impurity by paying to Pharma companies?

2019, Volume 4, Issue 3, Sept-Dec [Download full PDF]


Review

Top Pharma companies not following current good manufacturing processes: Angiotensin II receptor blockers with carcinogenic impurities: A threat to global public health

2019, Volume 4, Issue 3, Sept-Dec [Download full PDF]